Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Liabilities and Shareholders Equity (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of Liabilities and Shareholders Equity data on record, last reported at $14098.0 in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 55.91% year-over-year to $14098.0; the TTM value through Dec 2025 reached $96873.0, down 41.9%, while the annual FY2025 figure was $14098.0, 55.91% down from the prior year.
  • Liabilities and Shareholders Equity reached $14098.0 in Q4 2025 per ACBM's latest filing, up from $4323.0 in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $938874.0 in Q1 2021 and bottomed at $4323.0 in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $364818.5, with a median of $298803.5 recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 97.04% in 2023, then surged 103.27% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $761077.0 in 2021, then fell by 9.67% to $687486.0 in 2022, then plummeted by 91.5% to $58459.0 in 2023, then crashed by 45.31% to $31974.0 in 2024, then crashed by 55.91% to $14098.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $14098.0 in Q4 2025, $4323.0 in Q3 2025, and $53277.0 in Q2 2025.